Compounded Semaglutide: What “Compounded” Actually Means and Why Regulators Warn Against It

A reader recently sent us a photo of her refrigerator door: a carton of eggs, a jar of pickles and, tucked behind the oat milk, a small glass vial with a handwritten label. A friend had recommended the online clinic. The vial arrived in a padded envelope with a bag of syringes and a two-page instruction sheet. “Is this the real thing?” she asked. It is a fair question, and one that millions of people are typing into search engines right now.

The reason compounded semaglutide is trending, as of mid-2025, is a regulatory pivot. In February 2025 the US Food and Drug Administration declared the years-long shortage of the approved semaglutide products over, and it set spring deadlines for pharmacies to stop producing copies. The ads did not stop. Neither did the questions, the poison-center calls or the warning letters.

So let us take the vial out of the fridge and look at it properly: what “compounded” actually means, how it differs from the pen your endocrinologist would prescribe, and what the evidence can and cannot tell you.

What changed recently: why compounded semaglutide is in the headlines

The story begins with a shortage. In 2022, demand for semaglutide, first marketed for type 2 diabetes as Ozempic and later for chronic weight management as Wegovy, outran supply. When the FDA lists a drug as “in shortage,” federal law temporarily allows compounding pharmacies to make copies of it, on the reasoning that an imperfect version is better than no medicine for a patient who needs one. A cottage industry grew almost overnight.

The warnings followed quickly. In June 2024 the World Health Organization issued a global medical product alert after falsified semaglutide pens were identified in Brazil, the United Kingdom and the United States. A month later, US regulators published a safety communication describing dosing errors with compounded semaglutide, including patients who drew up several times the intended amount because the vial was labeled differently from the pen they had read about.

Then came the pivot. On February 21, 2025, the FDA determined that the semaglutide shortage had resolved. Smaller pharmacies were given until April 22, 2025, and larger outsourcing facilities until May 22, 2025, to wind down production of copies. After those dates, making a compounded version of a commercially available semaglutide product is generally not permitted unless a prescriber documents a genuine clinical need that the approved product cannot meet.

That is the practical reason this topic is spiking. Many people who started a compounded product during the shortage are now being told it will no longer be supplied, and they are searching for what that means. Others are seeing advertisements that quietly reframe the product as “personalized” or “with added vitamins” to slip through the exception. The regulatory position, though, has not softened: these products were never approved, and the temporary door has largely closed.

What does "compounded" actually mean in pharmacy?

Compounding is the practice of a pharmacist combining, mixing or altering ingredients to create a medicine tailored to one patient. That is a legitimate, sometimes essential service. A toddler who cannot swallow tablets may need a liquid version of a drug that only comes as pills. A patient allergic to a dye or preservative may need a version without it. Hospitals compound intravenous nutrition bags every day.

US law recognizes two tiers. A “503A” pharmacy is a state-licensed pharmacy that compounds a specific prescription for a specific named patient; it is regulated mainly by the state board of pharmacy. A “503B” outsourcing facility is registered with the FDA, may produce larger batches without a patient name attached, and must follow current good manufacturing practice, the quality system that regulates how approved medicines are made. Outsourcing facilities are inspected more rigorously, but their products are still not FDA-approved.

That last phrase is the hinge of the whole discussion. Approval means an independent regulator has reviewed the clinical trials, inspected the factory, examined how the drug is tested for purity and potency, and signed off on every word of the label. Compounded medicines skip that entire process by design. The assumption is that a pharmacist is making a small, individualized adjustment to something already known, not producing thousands of vials of a novel formulation shipped nationwide.

There is one more rule that matters here. Pharmacies are not allowed to compound what is “essentially a copy” of a commercially available drug. The shortage created a temporary exception. When a product is not in shortage, adding a splash of vitamin B12 or changing the strength slightly does not, on its own, turn a copy into a legitimate individualized prescription. Regulators have said so explicitly.

Compounded semaglutide vs Ozempic and Wegovy: is it the same drug?

The molecule may be the same. The medicine is not. That distinction sounds pedantic until you consider what a medicine actually is: an active ingredient plus a formulation, a delivery device, a manufacturing process, a stability profile and a label, all verified to behave the same way every single time.

Approved semaglutide arrives in a prefilled pen. The manufacturer has demonstrated to regulators that each pen delivers a consistent amount, that the solution remains stable through its labeled shelf life, that the product is sterile and free of visible particles, and that the injection technique described in the leaflet produces the blood levels studied in clinical trials.

Compounded semaglutide is assembled from bulk active pharmaceutical ingredient, the raw drug powder, purchased from a chemical supplier. The pharmacy dissolves it, sometimes adds other substances, fills it into multi-use vials and attaches its own label. Whether that particular vial contains the amount of drug stated on it, whether the drug degrades over the weeks it sits in a refrigerator, and whether any bacteria slipped in during filling are open questions that nobody has been required to answer.

Independent laboratory analyses of compounded GLP-1 products have found some vials with less active drug than labeled, some with more, and some containing impurities not present in the approved product. These are small studies, not comprehensive surveys, but they illustrate the core problem: variability that the approval process exists to eliminate.

People sometimes describe compounded semaglutide as “the generic.” There is no approved generic semaglutide in the United States; the patents have not expired. A generic would have to prove bioequivalence, meaning it delivers the same drug levels in the body as the original. Compounded products are exempt from that requirement, which is precisely why they are not generics.

How semaglutide works in the body

Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1 is a hormone your small intestine releases after a meal; an agonist is a drug that activates the same receptor the natural hormone does. The medicine is a modified copy of the hormone, tweaked so it lasts about a week in the bloodstream instead of a few minutes, which is why the approved injectable forms are taken once weekly.

Its effects run along three tracks. In the pancreas, it boosts insulin release when blood sugar is high and dampens glucagon, the hormone that pushes sugar out of the liver; this is why it lowers blood glucose in type 2 diabetes without usually causing dangerous lows on its own. In the stomach, it slows emptying, so a meal sits longer and fullness arrives sooner. In the brain, it acts on appetite centers in the hypothalamus and brainstem, quieting the background hum of hunger that people with obesity often describe as constant.

The result, in randomized trials, is substantial weight loss and better glucose control in people who continue the medicine. The result when the medicine stops is equally clear: appetite returns and much of the weight comes back within a year. Semaglutide manages a chronic condition; it does not reset it.

Currently approved uses in the United States include type 2 diabetes, chronic weight management in adults and adolescents who meet weight criteria, and, since March 2024, reducing the risk of heart attack, stroke and cardiovascular death in adults with established heart disease and overweight or obesity. An oral tablet form, Rybelsus, is approved for type 2 diabetes. Each approval rests on its own set of trials and its own label; compounded versions inherit none of them.

Why regulators warn against compounded semaglutide

Regulators do not object to compounding in principle. Their concern with compounded semaglutide rests on four specific, documented problems.

The first is that nobody checks the product before it reaches you. There is no pre-market review of potency, purity or sterility. A vial that is 30 percent under strength will look identical to one that is 30 percent over. Injectable medicines are held to especially strict sterility standards because bacteria injected under the skin bypass every defense the body has; a compounding error in injectable steroids caused a fatal meningitis outbreak in 2012 that reshaped US compounding law.

The second is dosing. Approved pens deliver a fixed, click-counted amount. Compounded products come in vials and are drawn up with syringes marked in units designed for insulin. Regulators have received reports of patients, and in some cases clinicians, misreading the label and administering many times the intended amount, followed by severe vomiting, dehydration and emergency visits.

The third is ingredient substitution. Some compounders have used semaglutide sodium or semaglutide acetate, salt forms that are not the active ingredient in any approved product and have not been shown to be safe or effective. More on that below.

The fourth is the supply chain itself. The WHO’s 2024 alert described falsified pens circulating in three countries, some containing no semaglutide at all and some containing insulin, which can cause life-threatening low blood sugar in a person who does not have diabetes. When a product is sold outside the regulated channel, the line between “compounded,” “counterfeit” and “unknown” blurs quickly.

Put plainly: the regulatory status of compounded semaglutide is that it is an unapproved drug, permitted only in narrow circumstances, and never intended for self-directed use or over-the-internet sale to the general public.

The salt problem: semaglutide sodium and semaglutide acetate

Here is a piece of chemistry that turns out to matter a great deal. Many drugs are supplied as salts, meaning the active molecule is bonded to another ion such as sodium or acetate to make it more stable or easier to dissolve. Sometimes the salt form is interchangeable with the base form; sometimes it changes how the drug is absorbed, how long it lasts, or how it behaves in solution.

Approved semaglutide products contain semaglutide base. No approved product contains semaglutide sodium or semaglutide acetate. Yet during the shortage years, regulators found compounders and telehealth marketers advertising products made from these salts, sometimes without disclosing it. The FDA stated that these salts are different active ingredients, that they had not been shown to be safe or effective, and that they did not meet the legal criteria for bulk substances that may be used in compounding at all.

Why would a compounder use a salt form? Availability and price of the raw material are the usual reasons. Chemical suppliers, some of them overseas and some marketing to the “research” sector rather than to pharmacies, sell peptide salts more readily than the base compound. The pharmacy may not always know exactly what it has received, and the patient almost certainly does not.

What is unknown here is not trivial. Nobody has measured whether a given salt form produces the same blood levels, the same stability in a vial over four weeks, or the same rate of degradation products. In pharmacology, “probably similar” is not a standard; it is a hypothesis awaiting a study that, for these products, has never been done.

If you have a compounded product and the label mentions a salt form, or lists the ingredient in any way other than “semaglutide,” that is worth showing your prescriber.

Why vials and syringes lead to dosing mistakes

Picture two people starting the same medicine. The first receives a pen. She turns a dial until the number on the label matches the number her doctor wrote, presses a button, and counts the clicks. The second receives a vial and a bag of syringes. His instruction sheet says to draw up a certain number of “units,” a measure borrowed from insulin dosing. His prescriber talks in milligrams. The vial lists a concentration in milligrams per milliliter. He now has to convert between three systems using a syringe barrel with markings a millimeter apart.

Most people manage. Enough do not that regulators felt compelled to publish a formal warning in July 2024. The reports included patients who confused units with milliliters, patients who misread a concentration and drew up a full syringe, and at least one case where a clinician’s instructions were transcribed incorrectly onto the pharmacy label. Some patients received several times, and in a few reports well over ten times, the intended amount.

Semaglutide overdose is rarely fatal on its own, but it is miserable and occasionally dangerous. Reported effects include prolonged, intractable vomiting; dehydration severe enough to injure the kidneys; abdominal pain; and, in people also taking insulin or sulfonylureas, serious low blood sugar. Because the drug lingers for about a week, symptoms can persist for days after a single error. US poison control centers reported a marked rise in semaglutide-related calls during the years compounded products were widespread.

The lesson is not that patients are careless. It is that medication safety is engineered, not assumed. A prefilled pen is a safety device as much as a delivery device. When you remove it, you shift the arithmetic onto the kitchen counter, and arithmetic errors at the kitchen counter are a well-documented cause of harm across every injectable medicine ever studied.

What the evidence actually says about compounded semaglutide

Evidence in medicine comes in grades, and it is worth being explicit about them here because the two products occupy opposite ends of the scale.

For approved semaglutide, the evidence is strong. The STEP 1 trial randomly assigned 1,961 adults with overweight or obesity, without diabetes, to weekly semaglutide or placebo alongside lifestyle counseling. After 68 weeks, the semaglutide group lost an average of 14.9 percent of body weight versus 2.4 percent with placebo. The SELECT trial followed 17,604 adults with established cardiovascular disease and overweight or obesity for a median of about 40 months and found a 20 percent relative reduction in major cardiovascular events. The SUSTAIN program established glucose-lowering in type 2 diabetes. These are large, randomized, placebo-controlled trials, the highest tier of clinical evidence, and they are the reason the medicine is approved.

For compounded semaglutide, there are no randomized trials. None. There are no bioequivalence studies demonstrating that a compounded vial produces the same blood levels as the pen. There are no stability studies published under regulatory oversight. What exists is the lowest tier: case reports of adverse events, regulatory adverse-event databases that cannot distinguish a product problem from a prescribing problem, and a handful of small laboratory analyses of purchased vials.

Between those tiers sits expert opinion. Major US professional societies in endocrinology and obesity medicine have issued statements recommending against compounded GLP-1 products outside narrow, documented circumstances. Expert opinion is a legitimate form of evidence, but it is the weakest grade, and it should be read as “we do not know enough and the risks are real,” not as proof of harm.

A candid summary: the approved medicine has some of the best evidence of any weight-management drug in history. The compounded copies have effectively none. Anyone claiming that compounded semaglutide “works just as well” is making an assumption, not citing a study.

Approved vs compounded semaglutide at a glance

The table below sets the two side by side on the features that matter for safety. It is deliberately short on adjectives. Where a cell says “unknown,” that is the precise scientific answer, not a rhetorical one.

Feature	Approved semaglutide (Ozempic, Wegovy, Rybelsus)	Compounded semaglutide
FDA approval	Yes, with reviewed clinical trials and label	No
Active ingredient	Semaglutide base, verified each batch	Varies; salt forms have been used
Randomized trial evidence	Multiple large trials (STEP, SELECT, SUSTAIN)	None
Potency testing before sale	Required, every lot	Not required for 503A; variable for 503B
Sterility assurance	Manufactured under good manufacturing practice	Depends on pharmacy; not independently verified
Delivery device	Prefilled pen with fixed dose settings	Multi-use vial and syringe
Stability data	Established shelf life on label	Unknown; no required studies
Added ingredients	None beyond approved formulation	Sometimes vitamins or other substances, untested in combination
Adverse-event reporting	Mandatory for manufacturer	Voluntary and inconsistent
Legal status after May 2025	Prescription medicine	Generally not permitted as a copy of an available product

Two rows deserve a second look. “Stability data: unknown” means that a vial opened on day one and used through day 28 may not contain the same amount of active drug at the end as at the start; peptides are fragile molecules that degrade with warmth, light and repeated needle punctures. And “added ingredients” is not a bonus feature. Mixing vitamin B12 or other compounds into the same vial changes the chemistry of the solution in ways nobody has studied, and it is often done specifically to argue that the product is no longer a “copy.”

Compounded semaglutide side effects: the known and the unknown

Start with what is well characterized, because it applies to any semaglutide product. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation and abdominal discomfort. In the STEP 1 trial, roughly three quarters of participants on semaglutide reported at least one such symptom, most often mild to moderate and easing over weeks as the body adjusts. Fatigue, headache and dizziness are also reported. Loss of muscle mass alongside fat is a recognized concern that clinicians address with protein intake and resistance exercise.

Less common but more serious effects include acute pancreatitis/">pancreatitis, gallbladder disease including gallstones, kidney injury usually secondary to dehydration from vomiting, and low blood sugar when combined with insulin or sulfonylureas. The approved products carry a boxed warning about thyroid C-cell tumors seen in rodent studies; whether this translates to people is unresolved, and the medicine is not prescribed to those with a personal or family history of medullary thyroid cancer. Slowed stomach emptying has prompted anesthesia guidance about fasting before procedures. Rapid improvement in blood sugar can temporarily worsen diabetic eye disease.

Now the layer that compounding adds. Because the dose may be wrong, the ordinary side effects can arrive at unusual intensity: the intractable vomiting and dehydration described in regulatory reports. Because sterility is unverified, injection-site infections, abscesses and, in the worst case, bloodstream infections become possible in a way they essentially are not with a factory-sealed pen. Because the ingredient may be a salt form or may contain impurities, allergic reactions or effects that have never been catalogued cannot be ruled out.

The honest framing is this: with the approved medicine, you and your clinician are managing a known list of risks with known frequencies. With a compounded product, you are managing that same list plus a second, uncharacterized one.

Common myths about compounded semaglutide, corrected

Viral claims travel faster than package inserts. Here are the ones we hear most, and what the evidence supports.

“It is the same molecule, so it is the same medicine.” The molecule is necessary but not sufficient. Formulation, sterility, stability and dose accuracy are what turn a molecule into a medicine, and none of those are verified in a compounded product. Some compounded versions have not even used the same molecule, substituting salt forms.

“The pharmacy is licensed, so the product is FDA-approved.” A pharmacy license permits a pharmacist to practice. It says nothing about whether a specific product has been reviewed. No compounded drug is FDA-approved; that is the definition of compounding.

“It is basically the generic version.” There is no approved generic semaglutide in the United States. Generics must prove they deliver the same drug levels as the brand. Compounded products are exempt from that proof.

“The added vitamin B12 prevents nausea.” No randomized trial has tested this. Vitamin B12 has no established role in preventing GLP-1-related nausea, and adding any substance to a peptide solution without stability testing introduces its own uncertainty.

“If a telehealth site offers it, it must be legal.” Legality depends on whether the product is a copy of a commercially available drug, whether that drug is in shortage, and whether state and federal rules are being followed. Since spring 2025 the shortage exception has closed, and regulators have issued warning letters to online marketers.

“Compounded means personalized.” Genuine personalization means a documented clinical reason the approved product will not work for you, such as an allergy to an inactive ingredient. Shipping the same vial to thousands of customers is mass production under a different name.

"Research peptides" and gray-market semaglutide: what they are

Beneath compounded semaglutide sits a murkier tier. Online storefronts sell vials of semaglutide labeled “for research use only” or “not for human consumption.” The label is doing legal work, not descriptive work: it is an attempt to sell a drug without being subject to drug law, on the fiction that the buyer is a laboratory rather than a person with a refrigerator and a syringe.

These products are unapproved medicines. They are not compounded by a pharmacist, not prescribed by a clinician, not manufactured under any inspected quality system, and not legal to sell for human use. Their contents have not been independently verified, and the WHO alert of 2024 is a reminder that some products sold as semaglutide have contained no semaglutide at all, while others contained insulin. The regulatory position is unambiguous: these products are not for sale to the public and are not for self-use.

Counterfeit pens occupy the same gray zone from a different direction. They mimic the packaging of approved products closely enough to fool a casual look. Reports have described counterfeit pens with incorrect needle types, batch numbers that do not match the label, and contents that ranged from diluted drug to entirely different medicines.

Why do people go there? Usually because the approved medicine was unavailable, unaffordable or not prescribed, and the marketing filled the gap with confidence and speed. Those are real frustrations, and they deserve a real answer from the healthcare system rather than a lecture. But the answer is not a vial of unknown provenance. A person with obesity or diabetes is managing a chronic condition that raises cardiovascular risk; adding an untested injectable to that picture compounds the risk rather than reducing it.

If you have a product you suspect is counterfeit or gray-market, do not use it. Bring it to a pharmacist or prescriber, who can help you identify it and report it.

Who is semaglutide actually for, and what to ask your clinician

The eligibility criteria for approved semaglutide are specific, and they exist because the trials enrolled specific populations. For chronic weight management, the label covers adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol, alongside a reduced-calorie diet and increased physical activity. Adolescents aged 12 and older who meet weight criteria are also covered for the weight-management product. For type 2 diabetes, the medicine is one of several second-line options after lifestyle change and usually metformin, chosen partly for its cardiovascular benefits. The cardiovascular-risk indication applies to adults with established heart disease and overweight or obesity.

Whether semaglutide is right for a particular person is a clinical judgment that weighs those criteria against history, other medicines, kidney function, pregnancy plans, family thyroid history and personal goals. That decision belongs to the prescribing clinician, and this article is not a substitute for it.

If you have been using a compounded product, or are considering one, a good conversation with your prescriber might cover the following.

• What exactly is in the vial I have? Can you help me read the label, including whether it lists a salt form or added ingredients?
• Which pharmacy made it, and is it a state-licensed 503A pharmacy or an FDA-registered 503B facility?
• Is there a documented clinical reason I need a compounded version rather than the approved pen?
• How should I handle the transition if the compounded supply ends?
• What symptoms should prompt me to call you or seek urgent care?

None of these questions are accusatory. A prescriber who has been supervising your care will welcome them, and a marketer who has not may find them difficult to answer. That difference is itself useful information.

When to see a doctor

Every semaglutide product, approved or compounded, carries a list of situations that call for prompt medical attention. Compounded products add one more: uncertainty about what and how much you injected. Treat that uncertainty as a symptom in its own right.

Seek emergency care or call your local poison control center immediately if you believe you injected more than intended, especially if vomiting has begun and you cannot keep fluids down. Do the same for signs of severe low blood sugar: confusion, shakiness, sweating, slurred speech or loss of consciousness, particularly if you also take insulin or a sulfonylurea.

Contact your prescriber the same day for any of the following red flags.

• Severe, persistent abdominal pain, especially if it radiates to your back or comes with vomiting, which can signal pancreatitis.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or clay-colored stools, which can signal gallbladder disease.
• Vomiting or diarrhea lasting more than a day, dizziness on standing, very dark urine or passing little urine, which suggest dehydration that can injure the kidneys.
• Redness, warmth, swelling, pus or increasing pain at an injection site, or fever after an injection.
• A lump in the neck, hoarseness, trouble swallowing or shortness of breath.
• Sudden changes in vision if you have diabetes.
• Hives, facial or throat swelling, or difficulty breathing after a dose.
• Persistent low mood or thoughts of self-harm, which have been reported with weight-management medicines and should never be managed alone.

Do not stop or change any prescribed medicine on your own, and do not switch between a compounded product and an approved one without your clinician’s guidance; the two are not interchangeable and the timing matters. If you have a vial you are unsure about, bring it with you. Your prescriber or pharmacist can identify what it is and report a suspected product problem to the FDA’s MedWatch program, which is how regulators learn about harm in the first place.

Frequently asked questions

What is compounded semaglutide?

Compounded semaglutide is a version of the GLP-1 medicine prepared by a pharmacy or outsourcing facility from bulk raw ingredient rather than made by the licensed manufacturer. It is not FDA-approved, is not tested for potency, sterility or stability before sale, and usually comes in a multi-use vial rather than a prefilled pen. It was permitted only as a temporary measure during a drug shortage that US regulators declared resolved in February 2025.

Is compounded semaglutide safe?

Its safety has not been established, which is different from proven unsafe. There are no clinical trials of compounded semaglutide. What exists are regulatory reports of dosing errors, adverse events and use of unapproved salt forms, plus laboratory findings of variable potency. The approved medicine has a well-characterized risk profile from large trials; the compounded version adds an uncharacterized layer on top. Regulators and professional societies advise against it outside narrow, documented circumstances.

How does compounded semaglutide compare with Ozempic?

Ozempic is an FDA-approved product with verified potency, sterility, stability and a fixed-dose pen, backed by randomized trials in type 2 diabetes and cardiovascular risk reduction. Compounded semaglutide may contain the same molecule but has none of that verification, arrives in a vial requiring manual measurement, and has no trial evidence of its own. They are not interchangeable, and a clinician should supervise any transition between them.

What are the side effects of compounded semaglutide?

Expect the same side effects as any semaglutide product: nausea, vomiting, diarrhea, constipation and abdominal discomfort most commonly, with rarer risks of pancreatitis, gallbladder disease, dehydration-related kidney injury and low blood sugar when combined with certain diabetes drugs. Compounding adds risks of wrong dose, injection-site infection from unverified sterility, and reactions to impurities or additives. Severe abdominal pain, persistent vomiting or infection signs warrant prompt medical attention.

Why did the FDA say compounding had to stop?

Federal law allows pharmacies to compound copies of a commercially available drug only while it is officially in shortage. On February 21, 2025, the FDA determined the semaglutide shortage had resolved and gave pharmacies and outsourcing facilities until April 22 and May 22, 2025, respectively, to stop. After those dates, compounding a copy is generally not permitted unless a prescriber documents a specific clinical need the approved product cannot meet.

Is compounded semaglutide the same as generic semaglutide?

No. There is no FDA-approved generic semaglutide in the United States because patents remain in force. A generic must prove bioequivalence, meaning it produces the same drug levels in the body as the brand, and is manufactured under the same quality rules. Compounded products are exempt from both requirements. Calling a compounded vial a generic is a marketing shortcut, not a regulatory category.

What is semaglutide sodium, and why does it matter?

Semaglutide sodium and semaglutide acetate are salt forms, meaning the drug molecule is bonded to another ion. No approved product uses them. US regulators stated these salts are different active ingredients, have not been shown to be safe or effective, and do not qualify as substances permitted in compounding. Some compounders used them because raw material was easier to source. If your vial label mentions a salt, show it to your prescriber.

Can I keep using compounded semaglutide if I already started?

That decision belongs to your prescribing clinician, not to a website or an article. Bring the vial and its label to your appointment so your prescriber can identify what it contains and discuss whether and how to transition to an approved product. Do not switch on your own or combine products, because doses and formulations are not interchangeable. Report any unusual symptoms promptly.

What is a 503A versus a 503B compounding pharmacy?

A 503A pharmacy is state-licensed and compounds individual prescriptions for named patients, overseen mainly by the state pharmacy board. A 503B outsourcing facility registers with the FDA, can make larger batches, and must follow current good manufacturing practice, the quality system used for approved drugs. Outsourcing facilities face stricter inspection, but products from either type are not FDA-approved and have not undergone clinical testing.

How can I tell if a semaglutide product is counterfeit?

Do not try to judge by appearance alone; counterfeits are designed to pass a glance. Warning signs include packaging or lot numbers that do not match the manufacturer’s format, pens with unusual needles, a product labeled for research use, a price or source outside a licensed pharmacy, or no prescriber involvement. If in doubt, do not inject it. A pharmacist can verify the product and help report it to regulators.

References

• MedlinePlus: Semaglutide Injection
• Cleveland Clinic: GLP-1 Agonists
• WHO: Warning on falsified medicines used for diabetes treatment and weight loss

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.